New drug shows promise for Hard-to-Treat blood cancers
NCT ID NCT02290951
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times
Summary
This early-stage study tested a new drug called odronextamab (REGN1979) in 200 people with B-cell blood cancers like non-Hodgkin lymphoma and chronic lymphocytic leukemia that had stopped responding to prior treatments. The goal was to check the drug's safety and find the right dose. The drug works by helping the immune system attack cancer cells. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Assuta Ashdod University Hospital
Ashdod, Southern District, 7747629, Israel
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
CHU Hôpital Lyon Sud
Lyon, 69495, France
-
Centre Henri Becquerel
Rouen, Haute-Normandie, 76038, France
-
Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel)
Boston, Massachusetts, 02215, United States
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Hadassah Medical Center
Jerusalem, Jerusalem, 9112001, Israel
-
Institut Gustave Roussy
Villejuif, Île-de-France Region, 94800, France
-
Lady Davis Carmel Medical Center
Haifa, 3436212, Israel
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Meir Medical Center
Kfar Saba, Central District, 44281, Israel
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Rambam Health Care Campus - Hematology and Bone Marrow Transplantation Institute
Haifa, 3109601, Israel
-
Royal Cornwall Hospitals NHS Trust
Truro, Cornwall, tr1 3lq, United Kingdom
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
-
Stanford University
Stanford, California, 94305, United States
-
The Chaim Sheba Medical Center
Tel-Hashomer, Central District, 5265601, Israel
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
Universitatsklinikum Wurzburg
Würzburg, Bavaria, 97080, Germany
-
University of California, Irvine
Orange, California, 92868, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.